Fake Tirzepatide Lawsuits Filed by Lilly; WHO Adds Its Own Warnings

The war against fake GLP-1 inhibitors is heating up, with Eli Lilly filing six suits against med spas and wellness centers selling unapproved versions of its patented tirzepatides — Mounjaro and Zepbound — with WHO also issuing an alert on the problem.

Lilly’s suits were filed in courts of Ohio, Texas, Hawaii and the District of Columbia, charging that these businesses claim falsely that their compounded versions of tirzepatide are FDA-approved, the company said in a press statement.

WHO issued a medical product alert targeting counterfeit semaglutide, which was detected last year in Brazil, the UK and the US. NovoNordisk, which makes the FDA-approved semaglutide Ozempic and Wegovy, confirmed that it did not manufacture the suspect batches, the company said.

To read the whole story, click here.

Related Topics